70 Participants Needed

Melatonin for Neonatal Hypoxic-Ischemic Encephalopathy

Recruiting at 1 trial location
KB
LS
SG
Overseen ByShaveka Gaskins, MBBS, Bsc
Age: < 18
Sex: Any
Trial Phase: Phase < 1
Sponsor: University of Florida
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 2 JurisdictionsThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

Hypoxic-Ischemic Encephalopathy (HIE) occurs in 20 per 1000 births. Only 47% of neonates treated with the state of the art therapy (induced systemic hypothermia) have normal outcomes. Therefore, other promising therapies that potentially work in synergy with hypothermia to improve neurologic outcomes need to be tested. One potential agent is melatonin. Melatonin is a naturally occurring substance produced mainly from the pineal gland. Melatonin is widely known for its role in regulating the circadian rhythm, but it has many other effects that may benefit infants with HI injury. Melatonin serves as a free radical scavenger, decreases inflammatory cytokines, and stimulates anti-oxidant enzymes. Therefore, melatonin may interrupt several key components in the pathophysiology of HIE, in turn minimizing cell death and improving outcomes. The research study will evaluate the neuroprotective properties and appropriate dose of Melatonin to give to infants undergoing therapeutic hypothermia for hypoxic ischemic encephalopathy.

Will I have to stop taking my current medications?

The trial information does not specify whether participants need to stop taking their current medications.

What data supports the effectiveness of the drug melatonin for treating neonatal hypoxic-ischemic encephalopathy?

Research shows that melatonin has neuroprotective properties, such as reducing inflammation and preventing cell death, which can help protect newborn brains from damage caused by lack of oxygen. Studies in animals and some early human trials suggest melatonin is safe and may improve outcomes for infants with this condition.12345

Is melatonin safe for use in humans, particularly for neonatal brain protection?

Melatonin appears to be safe for use in humans, with studies suggesting it is beneficial in protecting newborn brains from injury and has been used safely in children with sleep problems.56789

How is the drug melatonin unique in treating neonatal hypoxic-ischemic encephalopathy?

Melatonin is unique because it can cross all physiological barriers to reach subcellular compartments, offering neuroprotection through its antioxidant, anti-apoptotic (preventing cell death), and anti-inflammatory actions. It is considered safe and effective, but more large-scale human trials are needed to confirm its benefits in treating neonatal hypoxic-ischemic encephalopathy.125810

Research Team

Michael Weiss, M.D. — Gastro Florida

Michael Weiss

Principal Investigator

University of Florida

Eligibility Criteria

This trial is for newborns over 36 weeks gestation with Hypoxic-Ischemic Encephalopathy (HIE). They must have had an acute event at birth, show signs of brain dysfunction early on, and meet specific blood criteria. Infants already receiving cooling therapy within 6 hours of birth are eligible. Those with suspected meningitis, metabolic disorders, severe hypoglycemia, or significant congenital issues cannot participate.

Inclusion Criteria

The pH level in the cord or newborn baby's blood is less than 7.0.
My newborn had a low Apgar score or needed help breathing after birth.
My newborn was cooled within 6 hours of birth.
See 7 more

Exclusion Criteria

I was born with abdominal issues and other birth defects or genetic conditions.
I show signs of meningitis during a sepsis check.
I have high ammonia levels and low blood sugar.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment

Participants receive melatonin in a dose-escalation study alongside therapeutic hypothermia

3 days
Daily monitoring for 3 days

Follow-up

Participants are monitored for safety and effectiveness after treatment, including developmental follow-up at 18-22 months

18-22 months

Long-term safety and efficacy assessment

Evaluation of long-term safety and potential efficacy via developmental follow-up and MRI

18-22 months

Treatment Details

Interventions

  • Magnetic Resonance Imaging
  • Melatonin
  • Neurological Outcome Assessment
  • Pharmacokinetics
Trial OverviewThe study tests melatonin's ability to protect the brain in combination with induced hypothermia in infants suffering from HIE. It aims to find the right dose of melatonin that could help minimize brain cell death by acting as a free radical scavenger and reducing inflammation.
Participant Groups
3Treatment groups
Experimental Treatment
Group I: Participants 21-30Experimental Treatment4 Interventions
This group will receive Melatonin dose of 5 mg/kg enterally, only if the group Participants 11-20 has meet the safety goals. The first dose will be administered via enteral route within 12 hours of life with a target of 6 hours of life. The melatonin will be administered as a single dose for the first 5 participants in allowing the investigators to determine if the dosing frequency has the potential to decrease in the elimination with hypothermia. The next 5 subjects who will receive multiple doses if there are not any safety concerns. Additionally, the participants will have the following test performed: Magnetic Resonance Imaging (MRI), Neurological Outcome Assessment, Pharmacokinetics, and safety monitoring.
Group II: Participants 11-20Experimental Treatment4 Interventions
This group will the Melatonin dose of 3 mg/kg enteral, only if the group Participants 1-10 has meet the safety goals. The first dose will be administered via enteral route within 12 hours of life with a target of 6 hours of life. The melatonin will be administered as a single dose for the first 5 participants in allowing the investigators to determine if the dosing frequency has the potential to decrease in the elimination with hypothermia. The next 5 subjects who will receive multiple doses if there are not any safety concerns. Additionally, the participants will have the following test performed: Magnetic Resonance Imaging (MRI), Neurological Outcome Assessment, Pharmacokinetics, and safety monitoring.
Group III: Participants 1-10Experimental Treatment4 Interventions
This group will receive a 0.5 mg/kg enteral dose of Melatonin. The first dose will be administered via enteral route within 12 hours of life with a target of 6 hours of life. The melatonin will be administered as a single dose for the first 5 participants in allowing the investigators to determine if the dosing frequency has the potential to decrease in the elimination with hypothermia. The next 5 subjects who will receive multiple doses if there are not any safety concerns. Additionally, the participants will have the following test performed: Magnetic Resonance Imaging (MRI), Neurological Outcome Assessment, Pharmacokinetics, and safety monitoring.

Melatonin is already approved in European Union, United States for the following indications:

🇪🇺
Approved in European Union as Circadin for:
  • Insomnia in adults aged 55 and over
  • Sleep disorders in children with autism spectrum disorder
🇪🇺
Approved in European Union as Slenyto for:
  • Insomnia in children and adolescents aged 2-18 with autism spectrum disorder
🇺🇸
Approved in United States as Melatonin for:
  • Sleep disorders in children with autism spectrum disorder
  • Insomnia in adults

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Florida

Lead Sponsor

Trials
1,428
Recruited
987,000+

Thrasher Research Fund

Collaborator

Trials
135
Recruited
96,600+

Findings from Research

In a randomized controlled trial involving 80 newborns with hypoxic ischaemic encephalopathy, the addition of melatonin as adjunct therapy significantly improved survival rates, with 87% of the melatonin group surviving compared to 65% in the standard treatment group (p=0.03).
The study suggests that melatonin, administered at a dose of 10mg orally via nasogastric tube within 12 hours of birth, can be an effective treatment to enhance outcomes in newborns suffering from this condition.
Role of melatonin in management of hypoxic ischaemic encephalopathy in newborns: A randomized control trial.Ahmad, QM., Chishti, AL., Waseem, N.[2019]
In a study of 45 newborns, including 30 with hypoxic-ischemic encephalopathy (HIE), the combination of melatonin and hypothermia showed significant benefits, including fewer seizures and less white matter abnormalities on MRI compared to hypothermia alone.
The melatonin/hypothermia group demonstrated improved survival rates without neurological or developmental issues at 6 months, suggesting that early melatonin administration may help protect the brain in asphyxiated neonates.
Melatonin use for neuroprotection in perinatal asphyxia: a randomized controlled pilot study.Aly, H., Elmahdy, H., El-Dib, M., et al.[2022]
Melatonin shows promising neuroprotective properties, including antioxidant and anti-inflammatory effects, which could improve outcomes for infants with neonatal encephalopathy, especially when used alongside therapeutic hypothermia.
In studies using neonatal piglets, the effectiveness of melatonin is time-critical and dose-dependent, with optimal therapeutic levels needing to be reached within the first 2-3 hours after birth for the best results.
Melatonin for Neonatal Encephalopathy: From Bench to Bedside.Pang, R., Advic-Belltheus, A., Meehan, C., et al.[2022]

References

Role of melatonin in management of hypoxic ischaemic encephalopathy in newborns: A randomized control trial. [2019]
Melatonin use for neuroprotection in perinatal asphyxia: a randomized controlled pilot study. [2022]
Melatonin for Neonatal Encephalopathy: From Bench to Bedside. [2022]
[Research research on the use of melatonin in combination with therapeutic hypothermia for the treatment of neonatal hypoxic-ischemic encephalopathy]. [2023]
Melatonin in the management of perinatal hypoxic-ischemic encephalopathy: light at the end of the tunnel? [2020]
Long-term melatonin treatment for the sleep problems and aberrant behaviors of children with neurodevelopmental disorders. [2022]
Melatonin for sleep problems in children with neurodevelopmental disorders: randomised double masked placebo controlled trial. [2022]
Melatonin and the newborn brain. [2017]
[Treatment with ramelteon for sleep disturbance in severely disabled children and young adults]. [2018]
Melatonin for neuroprotection in neonatal encephalopathy: A systematic review & meta-analysis of clinical trials. [2021]